Literature DB >> 35247327

Structural basis for the catalytic activity of filamentous human serine beta-lactamase-like protein LACTB.

Minghui Zhang1, Laixing Zhang1, Runyu Guo1, Chun Xiao1, Jian Yin1, Sensen Zhang2, Maojun Yang3.   

Abstract

Serine beta-lactamase-like protein (LACTB) is a mammalian mitochondrial serine protease that can specifically hydrolyze peptide bonds adjacent to aspartic acid residues and is structurally related to prokaryotic penicillin-binding proteins. Here, we determined the cryoelectron microscopy structures of human LACTB (hLACTB) filaments from wild-type protein, a middle region deletion mutant, and in complex with the inhibitor Z-AAD-CMK at 3.0-, 3.1-, and 2.8-Å resolution, respectively. Structural analysis and activity assays revealed that three interfaces are required for the assembly of hLACTB filaments and that the formation of higher order helical structures facilitates its cleavage activity. Further structural and enzymatic analyses of middle region deletion constructs indicated that, while this region is necessary for substrate hydrolysis, it is not required for filament formation. Moreover, the inhibitor-bound structure showed that hLACTB may cleave peptide bonds adjacent to aspartic acid residues. These findings provide the structural basis underlying hLACTB catalytic activity.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  filament structure; human LACTB; hydrolysis activity; inhibitor binding site

Mesh:

Substances:

Year:  2022        PMID: 35247327     DOI: 10.1016/j.str.2022.02.007

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  2 in total

Review 1.  Unveiling the Function of the Mitochondrial Filament-Forming Protein LACTB in Lipid Metabolism and Cancer.

Authors:  Annunziata Cascone; Maciej Lalowski; Dan Lindholm; Ove Eriksson
Journal:  Cells       Date:  2022-05-20       Impact factor: 7.666

2.  LACTB, a Metabolic Therapeutic Target in Clinical Cancer Application.

Authors:  Xiaohua Li; Zhongkai Ren; Xiaohong Huang; Tengbo Yu
Journal:  Cells       Date:  2022-09-03       Impact factor: 7.666

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.